BioMS Medical to Present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
Toronto Stock Exchange Symbol: MS
EDMONTON, May 28 /PRNewswire-FirstCall/ -- BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Randy Stroud, Vice President Regulatory Affairs, will present at the Canadian Society for Pharmaceutical Sciences 12th Annual Meeting & Symposium.
TITLE: "Dirucotide: A Potential Therapy for Multiple Sclerosis"
WHEN: Thursday June 4th at 2:00 pm (Eastern Time)
WHERE: Hyatt Regency Hotel, Toronto, Ontario, Canada
About the Canadian Society for Pharmaceutical Sciences (CSPS)
CSPS is the premier organization for bringing together Pharmaceutical Scientists across Canada. The 12th Annual Meeting & Symposium focus is "Drug Development to Regulatory Approval".
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com/.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: BioMS Medical Corp.
CONTACT: Tony Hesby, Ryan Giese, Amanda Stadel, BioMS Medical Corp.,
(780) 413-7152, (780) 408-3040 Fax, E-mail: email@example.com, Internet:
http://www.biomsmedical.com/; James Smith, Investor Relations, (416) 815-0700
ext. 229, (416) 815-0080 Fax, E-mail: firstname.lastname@example.org
Posted: May 2009